Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Hormone Receptor Positive Breast Carcinoma|HER2-negative Breast Cancer|PIK3CA Mutant Metastatic Breast Cancer
Interventions: DRUG: Alpelisib|DRUG: Fulvestrant|DRUG: Aromatase inhibitor
Sponsor: Marina N Sharifi
Collaborators: Novartis|University of Wisconsin, Madison